Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CDK9 inhibitors in multiple myeloma: a review of progress and perspectives
Jędrzej Borowczak, Krzysztof Szczerbowski, Navid Ahmadi, et al.
Medical Oncology (2022) Vol. 39, Iss. 4
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Beyond cisplatin: New frontiers in metallodrugs for hard-to-treat triple negative breast cancer
Muhammad Nafees, Muhammad Hanif, Piaoping Yang
Coordination Chemistry Reviews (2023) Vol. 499, pp. 215507-215507
Closed Access | Times Cited: 26
Targeting Myc-driven stress addiction in colorectal cancer
Haris Saeed, Brian J. Leibowitz, Lin Zhang, et al.
Drug Resistance Updates (2023) Vol. 69, pp. 100963-100963
Open Access | Times Cited: 23
Identification of a Novel Selective CDK9 Inhibitor for the Treatment of CRC: Design, Synthesis, and Biological Activity Evaluation
Ye Zhong, Jing Xu, Ruochen Zhou, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 6, pp. 4739-4756
Closed Access | Times Cited: 14
Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent In Vivo Activities in Mouse Models of Hematological and Solid Tumors
James C. Tarr, James M. Salovich, Martin Aichinger, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 16, pp. 14370-14393
Open Access | Times Cited: 6
Insight Study For Repurposing Of Certain Anti‐Inflammatory Drugs Based On Aspirin and Salicylic Acid Scaffolds For The Treatment of Cancer as CDKs Inhibitors: Cheminformatics and Anticancer Studies
Mohnad Abdalla, Ahmed E. Elmasry, Mohamed T. M. Nemr, et al.
ChemistrySelect (2025) Vol. 10, Iss. 15
Closed Access
Addressing Transcriptional Dysregulation in Cancer through CDK9 Inhibition
Mohammed A. Toure, Angela N. Koehler
Biochemistry (2023) Vol. 62, Iss. 6, pp. 1114-1123
Open Access | Times Cited: 10
Discovery of new imidazole[1,2-a] pyridine derivatives as CDK9 inhibitors: Design, synthesis and biological evaluation
Zihan Sun, Shudong Sun, Xiong Li, et al.
RSC Medicinal Chemistry (2025)
Closed Access
Signal transduction pathways controlling Ins2 gene activity and beta cell state transitions
Chieh Min Jamie Chu, Bhavya Sabbineni, Haoning Howard Cen, et al.
iScience (2025) Vol. 28, Iss. 3, pp. 112015-112015
Open Access
Rethinking MYC inhibition: a multi-dimensional approach to overcome cancer’s master regulator
Shiyu Liu, Dan Liu, Y Yuan, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 13
Open Access
Mechanistic Roles of Transcriptional Cyclin-Dependent Kinases in Oncogenesis: Implications for Cancer Therapy
Mohammed Alrouji, Mohammed S. Alshammari, Saleha Anwar, et al.
Cancers (2025) Vol. 17, Iss. 9, pp. 1554-1554
Open Access
Histone‐lysine N‐methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc‐driven liver cancer
Dexter Kai Hao Thng, Lissa Hooi, Clarissa Chin Min Toh, et al.
Molecular Oncology (2023) Vol. 17, Iss. 11, pp. 2275-2294
Open Access | Times Cited: 9
Discovery of novel CDK9 inhibitor with tridentate ligand: Design, synthesis and biological evaluation
Ye Zhong, Jing Xu, Shaoyue Ding, et al.
Bioorganic Chemistry (2024) Vol. 150, pp. 107550-107550
Closed Access | Times Cited: 2
Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs): bench to bedside.
Ali Hassanzadeh, Navid Shomali, Amin Kamrani, et al.
PubMed (2024) Vol. 23, pp. 862-882
Closed Access | Times Cited: 2
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers
Arany Soosainathan, Marjan Iravani, Rania El Botty, et al.
Cancer Research (2023) Vol. 84, Iss. 1, pp. 17-25
Open Access | Times Cited: 5
Therapeutic Path to Triple Knockout: Investigating the Pan-inhibitory Mechanisms of AKT, CDK9, and TNKS2 by a novel 2-Phenylquinazolinone derivative in Cancer Therapy- An In-Silico Investigation
Xylia Q. Peters, Ghazi Elamin, Aimen Aljoundi, et al.
Current Pharmaceutical Biotechnology (2023) Vol. 25, Iss. 10, pp. 1288-1303
Closed Access | Times Cited: 4
MDFit: automated molecular simulations workflow enables high throughput assessment of ligands-protein dynamics
Alexander C. Brueckner, Benjamin Shields, Palani Kirubakaran, et al.
Journal of Computer-Aided Molecular Design (2024) Vol. 38, Iss. 1
Closed Access | Times Cited: 1
Bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM): Therapeutic implications
Osman Aksoy, Judith Lind, Vincent Sunder-Plaßmann, et al.
Cytokine (2022) Vol. 161, pp. 156062-156062
Open Access | Times Cited: 6
CDK9 Inhibitor Induces Apoptosis, Autophagy, and Suppression of Tumor Growth in Adult T-Cell Leukemia/Lymphoma
Naho Kato, Tomohiro Kozako, Takeo Ohsugi, et al.
Biological and Pharmaceutical Bulletin (2023) Vol. 46, Iss. 9, pp. 1269-1276
Open Access | Times Cited: 3
Dinaciclib synergizes with BH3 mimetics targeting BCL‐2 and BCL‐XL in multiple myeloma cell lines partially dependent on MCL‐1 and in plasma cells from patients
Manuel Beltrán‐Visiedo, Nelia Jiménez‐Alduán, Rosana Díez, et al.
Molecular Oncology (2023) Vol. 17, Iss. 12, pp. 2507-2525
Open Access | Times Cited: 2
The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies
Fusheng Zhou, Lili Tang, Siyuan Le, et al.
Oncotarget (2023) Vol. 14, Iss. 1, pp. 997-1008
Open Access | Times Cited: 2
Transforming growth factor-β (TGF-β) signaling pathway-related genes in predicting the prognosis of colon cancer and guiding immunotherapy
Jie Chen, Chao Ji, Silin Liu, et al.
Cancer Pathogenesis and Therapy (2023) Vol. 2, Iss. 4, pp. 299-313
Open Access | Times Cited: 1
Design, synthesis, and biological evaluation of dinaciclib and CAN508 hybrids as CDK inhibitors
Dana M. Odeh, Heba Abdelrasheed Allam, Fady Baselious, et al.
Drug Development Research (2024) Vol. 85, Iss. 3
Closed Access
Discovery of Novel Cdk9 Inhibitor with Tridentate Ligand: Design, Synthesis and Biological Evaluation
Yang Liu, Ye Zhong, Jing Xu, et al.
(2024)
Closed Access
Signal transduction pathways controllingIns2gene activity and β cell state transitions
Chieh Min Jamie Chu, Bhavya Sabbineni, Haoning Howard Cen, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Targeting CDKs with Other Chemotherapeutic Drugs: A Combinatorial Approach
Manzoor Ahmad Mir, Umar Y. Mir
(2023), pp. 269-289
Closed Access
Page 1 - Next Page

Scroll to top